Loading organizations...

§ Private Profile · San Mateo, CA, USA
Medical device company commercializing the TIF procedure for GERD, specializing in incisionless surgical technology.
Based in Redmond, Washington, EndoGastric Solutions is a medical device manufacturer that develops and commercializes the Transoral Incisionless Fundoplication procedure and Esophyx technology for treating gastroesophageal reflux disease. Founded in 2002 by Doctor Stefan K and Doctor Thomas J Fogarty, the enterprise provides an incisionless surgical alternative to traditional approaches, utilizing visual guidance to assist gastroenterologists and surgical specialists. Since receiving initial FDA clearance in 2007, the firm has launched its third-generation Z+ device and expanded regulatory labeling to include procedures performed concomitantly with hiatal hernia repair. Led by CEO Skip Baldino, the company has secured more than $150 million in venture capital and structured debt financing from prominent investors including Advanced Technology Ventures, Canaan Partners, and CRG. Recent clinical publications have demonstrated both the durability and efficacy of this minimally invasive procedural therapy for patients.
EndoGastric Solutions has raised $373.5M across 16 funding rounds.
EndoGastric Solutions has raised $373.5M in total across 16 funding rounds.
EndoGastric Solutions (EGS) is a medical device company based in Redmond, Washington, specializing in incisionless surgical technologies for treating gastroesophageal reflux disease (GERD).[1][2][3] It develops and commercializes products like the EsophyX Z device for the Transoral Incisionless Fundoplication (TIF) 2.0 procedure, a minimally invasive alternative to traditional surgery that addresses unmet needs between medications and invasive options, serving GERD patients and healthcare providers.[1][2][3] The company also offers supportive tools like the GERDHelp mobile app for symptom tracking and personalized education.[1] With around 100 employees and $25.1 million in revenue, EGS demonstrates growth momentum through an $18M financing round in 2022 to expand TIF adoption and international reach, including a 2017 European Early Access Program.[1][2][3]
EndoGastric Solutions emerged as a innovator in gastroenterology and surgery, combining advanced concepts to create incisionless GERD treatments, with its EsophyX Fastener Delivery System receiving CE Mark approval in 2006 and U.S. FDA clearance in 2007.[2] The company advanced to the third-generation EsophyX Z device in 2015, launching it in the U.S. before expanding internationally via partnerships like ab medica in Italy in 2017.[2] Leadership evolved significantly in 2022 when Darin Hammers, with over 30 years in medical devices (including CEO roles at DYSIS Medical and Cogentix Medical), became President and CEO, replacing Skip Baldino after eight years of transformations; the transition coincided with $18M financing to fuel commercialization.[3] Baldino continues as a strategic advisor, highlighting the company's focus on GERD patient relief.[3]
EndoGastric Solutions rides the trend toward minimally invasive endoscopic procedures in gastroenterology, addressing the growing GERD prevalence affecting millions amid rising demand for alternatives to lifelong medications or risky surgeries.[1][2][3] Timing aligns with post-2000s advancements in transoral technologies, enabling international expansion (e.g., CE-marked devices in Europe) and partnerships with distributors like ab medica.[2] Market forces favoring EGS include healthcare shifts to outpatient, cost-effective interventions and evidence-based devices, positioning it to influence the medtech ecosystem by expanding TIF access and reducing GERD burdens.[1][3]
EGS is poised for accelerated growth through TIF 2.0 commercialization, leveraging its 2022 $18M funding and new CEO's medtech expertise to penetrate international markets and boost U.S. adoption.[3] Trends like AI-enhanced patient apps (building on GERDHelp) and hybrid endo-surgical procedures will shape its path, potentially evolving its influence via broader GERD management ecosystems and partnerships.[1][2] As incisionless therapies gain traction, EGS could redefine GERD care, delivering life-changing relief at scale and solidifying its medtech leadership.[1][3]
EndoGastric Solutions has raised $373.5M in total across 16 funding rounds.
EndoGastric Solutions's investors include Uri Geiger, Mike Carusi, Canaan Partners, Canepa Advanced Healthcare Fund, Chicago Growth Partners, CRG, Radius Ventures, Sightline Partners, Brandon Capital Partners, Johnson & Johnson Innovation, Lightstone Ventures, Red Tree Venture Capital.
EndoGastric Solutions has raised $373.5M across 16 funding rounds. Most recently, it raised $18.0M Other Equity in December 2022.